.... In our experience, such responses were achieved using moderate doses (7 or 8 mg/m 2 ) of mitomycin, which also resulted in fewer hematologic and other toxicities. Delivery of MVP (mitomycin/vinca alkaloid/cisplatin) to 150 patients with stages III and IV NSCLC during the last decade showed maximal...